CONTEXT: There is a need for increased knowledge about endogenous sex hormone levels and clinical outcomes of risk/benefit. Immunoassays have poor specificity to reliably measure low steroid concentrations in elderly. OBJECTIVE: The objective of the study was to evaluate plasma steroid concentrations with regard to prevalent cardiovascular disease (CVD) in elderly, using mass spectrometry. SETTING: The study was conducted at a university hospital research unit. DESIGN AND METHODS: Plasma samples were analyzed from 202 70-yr-olds as part of a large population-based study, Prospective Investigation of the Vasculature in Uppsala Seniors. Twenty-eight of these had prevalent CVD. Eleven steroids were quantified, using liquid chromatography-tandem mass spectrometry. Women with current/previous menopausal hormone therapy (n = 35) were excluded. RESULTS: Men without prevalent CVD had higher plasma 17beta-estradiol (E2), compared with women. Men with prevalent CVD, compared with those without, had lower 17-hydroxypregnenolone (17OHPregn), 17-hydroxyprogesterone, and higher estrone/androstenedione and E2/testosterone (T) (aromatase activity). Women with prevalent CVD had lower pregnenolone, 17OHPregn, and dehydroepiandrosterone (DHEA) but higher DHEA/17OHPregn, androstenedione/DHEA, E2/T, E2/estrone, and E2/SHBG. The aromatase index, E2/T, was higher for prevalent CVD in both sexes. Adjustment for statin use, smoking, and body mass index yielded additional significant differences in men, whereas some were lost in women. Logistic regression indicated strong associations between prevalent CVD and low 17OHPregn, adjusted odds ratio of 0.18, 95% confidence interval (0.06-0.61); P = 0.006, in women and low 17-hydroxyprogesterone, 0.45 (0.25-0.80); P = 0.007 in men, most likely caused by increased throughput (consumption) toward estrogen synthesis. CONCLUSIONS: Prevalent CVD was associated with indications of lower androgen precursors, increased aromatase activity, and higher estrogen levels in both sexes. Results might represent an endogenous response to a condition of developing atherosclerosis, rather than a causative relationship. Furthermore studies are needed.
CONTEXT: There is a need for increased knowledge about endogenous sex hormone levels and clinical outcomes of risk/benefit. Immunoassays have poor specificity to reliably measure low steroid concentrations in elderly. OBJECTIVE: The objective of the study was to evaluate plasma steroid concentrations with regard to prevalent cardiovascular disease (CVD) in elderly, using mass spectrometry. SETTING: The study was conducted at a university hospital research unit. DESIGN AND METHODS: Plasma samples were analyzed from 202 70-yr-olds as part of a large population-based study, Prospective Investigation of the Vasculature in Uppsala Seniors. Twenty-eight of these had prevalent CVD. Eleven steroids were quantified, using liquid chromatography-tandem mass spectrometry. Women with current/previous menopausal hormone therapy (n = 35) were excluded. RESULTS:Men without prevalent CVD had higher plasma 17beta-estradiol (E2), compared with women. Men with prevalent CVD, compared with those without, had lower 17-hydroxypregnenolone (17OHPregn), 17-hydroxyprogesterone, and higher estrone/androstenedione and E2/testosterone (T) (aromatase activity). Women with prevalent CVD had lower pregnenolone, 17OHPregn, and dehydroepiandrosterone (DHEA) but higher DHEA/17OHPregn, androstenedione/DHEA, E2/T, E2/estrone, and E2/SHBG. The aromatase index, E2/T, was higher for prevalent CVD in both sexes. Adjustment for statin use, smoking, and body mass index yielded additional significant differences in men, whereas some were lost in women. Logistic regression indicated strong associations between prevalent CVD and low 17OHPregn, adjusted odds ratio of 0.18, 95% confidence interval (0.06-0.61); P = 0.006, in women and low 17-hydroxyprogesterone, 0.45 (0.25-0.80); P = 0.007 in men, most likely caused by increased throughput (consumption) toward estrogen synthesis. CONCLUSIONS: Prevalent CVD was associated with indications of lower androgen precursors, increased aromatase activity, and higher estrogen levels in both sexes. Results might represent an endogenous response to a condition of developing atherosclerosis, rather than a causative relationship. Furthermore studies are needed.
Authors: Johannes D Veldhuis; Olga P Bondar; Roy B Dyer; Sergey A Trushin; Eric W Klee; Ravinder J Singh; George G Klee Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Eric S Orwoll; Carrie M Nielson; Fernand Labrie; Elizabeth Barrett-Connor; Jane A Cauley; Steven R Cummings; Kristine Ensrud; Magnus Karlsson; Edith Lau; P C Leung; Osten Lunggren; Dan Mellström; Alan L Patrick; Marcia L Stefanick; Kozo Nakamura; Noriko Yoshimura; Joseph Zmuda; Liesbeth Vandenput; Claes Ohlsson Journal: J Clin Endocrinol Metab Date: 2010-07-28 Impact factor: 5.958
Authors: Samar R El Khoudary; Nanette Santoro; Hsiang-Yu Chen; Ping G Tepper; Maria M Brooks; Rebecca C Thurston; Imke Janssen; Sioban D Harlow; Emma Barinas-Mitchell; Faith Selzer; Carol A Derby; Elizabeth A Jackson; Daniel McConnell; Karen A Matthews Journal: Eur J Prev Cardiol Date: 2015-09-18 Impact factor: 7.804
Authors: Robin Haring; Zhaoyang Teng; Vanessa Xanthakis; Andrea Coviello; Lisa Sullivan; Shalender Bhasin; Joanne M Murabito; Henri Wallaschofski; Ramachandran S Vasan Journal: Clin Endocrinol (Oxf) Date: 2013-04 Impact factor: 3.478
Authors: Margus Viigimaa; Helena Vaverkova; Michel Farnier; Maurizio Averna; Luc Missault; Mary E Hanson; Qian Dong; Arvind Shah; Philippe Brudi Journal: Lipids Health Dis Date: 2010-11-04 Impact factor: 3.876
Authors: Thomas G Travison; Christopher J O'Donnell; Shalender Bhasin; Joseph M Massaro; Udo Hoffmann; Ramachandran S Vasan; Ralph B D'Agostino; Shehzad Basaria Journal: J Clin Endocrinol Metab Date: 2016-03-01 Impact factor: 5.958
Authors: Dirk Vanderschueren; Michaël R Laurent; Frank Claessens; Evelien Gielen; Marie K Lagerquist; Liesbeth Vandenput; Anna E Börjesson; Claes Ohlsson Journal: Endocr Rev Date: 2014-09-09 Impact factor: 19.871
Authors: Wesley T O'Neal; Saman Nazarian; Alvaro Alonso; Susan R Heckbert; Viola Vaccarino; Elsayed Z Soliman Journal: Endocrine Date: 2017-08-07 Impact factor: 3.633
Authors: Johanna Christina Penell; Mark M Kushnir; Lars Lind; Jonatan Bergquist; Jonas Bergquist; P Monica Lind; Tord Naessen Journal: Endocr Connect Date: 2021-05-13 Impact factor: 3.335
Authors: Yingya Zhao; Yu-Tang Gao; Xianglan Zhang; Alan L Rockwood; Mark M Kushnir; Qiuyin Cai; Jie Wu; Jiajun Shi; Qing Lan; Nathaniel Rothman; Yu Shyr; Xiao-Ou Shu; Wei Zheng; Gong Yang Journal: Int J Cancer Date: 2022-04-02 Impact factor: 7.316